A total of four investigational products targeting unmet medical needs have made it onto the European Medicines Agency’s priority medicines scheme so far this year.

Silicon BioDevices Inc. is looking to save critical time in heart attack diagnosis as well as billions of dollars in health care costs with the first lab-quality, reader-free, POC device for high-sensitivity measurement of cardiac troponin, a key marker of cardiac damage. Using one drop of whole blood, the company's self-contained blood test provides results within 15 minutes to determine whether or not a patient has experienced a heart attack.

This Month's Profile Groups: Ocular Gene Therapy Sees The Light, features profiles of Avalanche Biotechnologies, Eyevensys, GenSight Biologics, and Hemera Biosciences; Smart Orthopedic Implants, feature profiles of OrthoData and Ortho-tag. Plus these Start-Ups Across Health Care: Colibri Heart Valve, Complix, Helmedix, Mapi Pharma, Mendor, Oligomerix, QuantuMDx, Silicon BioDevices, and Vigilant Biosciences.